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Abstract
Oligo-anuric individuals receiving hemodialysis (HD) are dependent on the dialysis machine to 
regulate sodium and water balance. Interest in adjusting the dialysate sodium concentration to 
promote tolerance of the HD procedure dates back to the early years of dialysis therapy. Evolution 
of dialysis equipment technologies and clinical characteristics of the dialysis population have 
prompted clinicians to increase the dialysate sodium concentration over time. Higher dialysate 
sodium concentrations generally promote hemodynamic stabilization and reduce intradialytic 
symptoms but often do so at the expense of stimulating thirst and promoting volume expansion. 
The opposite may be true for lower dialysate sodium concentrations. Observational data suggest 
that the association between dialysate sodium and outcomes may differ by serum sodium levels, 
supporting the trend toward individualization of the dialysate sodium prescription. However, lack 
of randomized controlled clinical trial data, along with operational safety concerns related to 
individualized dialysate sodium prescriptions, have prevented expert consensus regarding the 
optimal approach to the dialysate sodium prescription.
The kidneys play a central role in the homeostasis of the internal environment. In addition to 
toxin clearance, acid-base and electrolyte balance and vital enzyme and hormone 
production, the kidneys regulate sodium and water balance. Oligo-anuric individuals with 
end-stage kidney disease receiving hemodialysis (HD) depend on the dialysis machine to 
remove the sodium and water accumulated over the interdialytic interval and do so while 
maintaining a relatively constant plasma sodium concentration.1 The obvious exogenous 
source of sodium is dietary, but a less obvious source may be the dialysate fluid itself. While 
dietary sodium restrictions have been shown to reduce blood pressure (BP),2 adherence to 
Corresponding Author: Jennifer E. Flythe MD, MPH, University of North Carolina Kidney Center, 7024 Burnett-Womack CB #7155, 
Chapel Hill, NC 27599-7155, jflythe@med.unc.edu, (tel) 919-445-2656, (fax) 919-966-4251. 
Disclosures
J.E.F. is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK109401 and has received 
speaking honoraria from Dialysis Clinic, Incorporated, Renal Ventures, American Renal Associates, American Society of Nephrology, 
Baxter and numerous universities and research funding for studies unrelated to dialysate sodium from the Renal Research Institute, a 
subsidiary of Fresenius Medical Care, North America. F.M.C is supported by National Institute of Diabetes and Digestive and Kidney 
Diseases grant K23DK102511 and has received consulting fees from GSK.
HHS Public Access
Author manuscript
Semin Dial. Author manuscript; available in PMC 2018 March 01.
Published in final edited form as:
Semin Dial. 2017 March ; 30(2): 99–111. doi:10.1111/sdi.12570.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
such restrictions are difficult to achieve in clinical practice, and often are not sufficient in 
isolation to maintain normal BP. On the other hand, dialysate sodium is a readily modifiable 
aspect of the HD prescription and is a potential complement to dietary sodium restriction in 
the effort to achieve euvolemia and BP control among individuals receiving HD therapy. The 
importance of dialysis for volume control was realized early by the dialysis pioneer Belding 
Scribner who observed, “…hypertension appears to be influenced by the size of the 
extracellular space. The combination of dietary sodium restriction and ultrafiltration during 
dialysis permits regulation of extracellular volume.”3
Dialysate sodium prescriptions have evolved over the last 50 years with changes driven by 
technological advances and desire to improve the tolerability of the HD procedure. In the 
modern era, with its emphasis on efficiency and safe delivery of therapy to large populations, 
bulk-prepared dialysate has become commonplace. As a result, dialysate composition has 
become relatively standardized across facilities, particularly in the United States (U.S.). 
Increasing clinical and regulatory scrutiny of facility volume management practices has 
sparked renewed interest in defining the optimal approach to dialysate sodium prescription 
with growing attraction to tailoring the dialysate sodium concentration to individual patient 
needs. Higher dialysate sodium concentrations generally promote hemodynamic 
stabilization and reduce intradialytic symptoms but often do so at the expense of stimulating 
thirst and promoting volume expansion. On the other hand, lower dialysate sodium may lead 
to less thirst and associated weight gain, but at the expense of greater hemodynamic 
instability. Observational data suggest that the association between dialysate sodium and 
outcomes may differ by serum sodium levels, supporting the trend toward individualization 
of the dialysate sodium. However, lack of randomized controlled clinical trial data in this 
area has hindered development of clear clinical guidelines regarding the optimal approach to 
the dialysate sodium prescription.
Herein, we review the history of dialysate sodium titration, consider technical nuances of 
sodium measurement, summarize the pathophysiology and existing evidence linking 
dialysate sodium prescription to clinical outcomes and identify future research needs.
History of Dialysate Sodium Titration
Approach to dialysate sodium prescription: the early years
When dialysis was pioneered in the 1940’s, Dr. Willem Kolff set the dialysate sodium 
concentration to 126.5 mEq/L (lower than the patient’s serum sodium), recognizing the 
importance of diffusive sodium removal to thirst and BP control.4 Potential unfavorable 
hemodynamic consequences of such a low dialysate sodium concentration were offset by the 
high glucose concentration of the dialysate. Coil dialyzer membranes were unable to 
withstand high transmembrane pressures, so ultrafiltration was performed by osmosis. A 
supra-physiologic dialysate glucose concentration (>1,800 mg/dL)5 was used to generate an 
osmotic gradient for fluid removal.4 If an isonatremic dialysate had been used under these 
conditions, patients would have become hypernatremic. As such, typical dialysate sodium 
concentrations ranged from 126 to 130 mEq/L.5 The combined osmolar effect of the 
dialysate glucose, and to a lesser extent dialysate sodium, concentrations promoted 
hemodynamic stability during HD. The use of lower dialysate sodium concentrations 
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remained commonplace through the 1960’s as administration of dialysis became more 
widespread.
Over time, as dialysis treatment times shortened, reports of headache, vomiting, blurred 
vision, tremors, seizures and disorientation began to accumulate in patients who were 
dialyzed with dialysate sodium concentrations <120 mEq/L.6 Collectively, these symptoms 
came to be known as the ‘dialysis disequilibrium syndrome’.7 As this symptom constellation 
was most commonly observed in patients initiating dialysis, several authorities attributed the 
syndrome to the combined effects of rapid volume removal and rapid shifts in plasma 
osmolality.8 Dialytic removal of urea as well as other osmotically-active molecules results in 
a decline of the extracellular osmolality relative to the intracellular osmolality. While urea is 
traditionally considered an ineffective osmole, very rapid clearance of urea by HD may 
generate a temporary, physiologically significant osmotic gradient between the intracellular 
and extracellular spaces.7, 9, 10 The pathophysiology of dialysis disequilibrium syndrome is 
not fully elucidated, but the syndrome’s clinical manifestations are largely attributable to 
cerebral edema.
These clinical observations, along with 1) the development of more resilient dialysis 
membranes, 2) introduction of hydrostatic ultrafiltration and 3) associated reduction in 
dialysate glucose concentrations, prompted use of higher dialysate sodium in subsequent 
years. By the 1960s, most facilities used a dialysate sodium concentration of 130 mEq/L.4 
Figure 1 provides an overview of dialysate sodium titration over time.
Recent trends in dialysate sodium prescription
During the 1970s and 1980s, dialysis technologies continued to evolve, allowing for even 
shorter treatment times. Secondarily, ultrafiltration rates increased and intradialytic 
hemodynamic instability became more common. Dialysate sodium concentrations were thus 
increased further to optimize intradialytic BP stability. By the 1980s the mean dialysate 
sodium concentration was 135 mEq/L.11 A decade later, the mean dialysate sodium had 
risen to 140 mEq/L, the most common concentration still today.12 To promote patient safety 
in hectic treatment environments, many facilities adopt facility-wide dialysate sodium 
prescriptions, standardizing prescriptions across all facility patients. In a 2011 study of 
almost 1,400 patients from a single dialysis provider, Munoz Mendoza et al. reported that 
over 50% of organization patients dialyzed with a dialysate sodium concentration of 140 
mEq/L.12
Data from numerous international sources suggest that mean pre-dialysis serum sodium 
concentrations range 136–139 mmol/L.12, 13 Since dialysis patients in the U.S. have a 
median serum sodium of ~138 mmol/L,14 use of the typical dialysate sodium concentration 
of 140 mEq/L will result in net diffusive sodium gains among a majority of patients.
Most dialysis prescriptions utilize a constant dialysate sodium concentration throughout the 
HD treatment, but varying the dialysate sodium concentration during treatment can be 
employed to maximize gains from sodium’s osmotic properties while minimizing associated 
fluid retention. Such sodium profiling (or modeling) utilizes a higher dialysate sodium early 
in the treatment with progressive reduction over the course of dialysis, concluding treatment 
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with a dialysate sodium concentration similar to or lower than plasma sodium levels. This 
approach promotes hemodynamic stabilization through a diffusive influx of sodium that 
corresponds to the timing of the rapid fall in plasma osmolality precipitated by removal of 
urea and other osmotically-active solutes early in the treatment. As the treatment progresses, 
the rapid decline in plasma osmolality abates and the dialysate sodium is concurrently 
lowered, which minimizes the development of hypertonicity and associated thirst and 
subsequent weight gains. In their 2011 study, Munoz-Mendoza et al. found that sodium 
modeling was ordered in over a third of HD prescriptions.12 However, most approaches to 
sodium modeling lead to ‘sodium loading’, as patients are exposed to a higher “time-
averaged” dialysate sodium concentration of 140–145 mEq/L (the relevant value when 
considering sodium balance).15, 16 Thus, sodium modeling has generally fallen out of favor 
in recent years due to concerns about resultant volume expansion. As an alternative to 
sodium modeling and, as further reviewed below, some clinicians now individualize the 
dialysate sodium concentration by aligning dialysate sodium prescriptions with patient pre-
dialysis serum sodium levels.
In the last 5 years, increasing recognition of volume control as a critical contributor to 
adverse outcomes among individuals receiving HD has heightened interest in dialysate 
sodium manipulation as a potential modifiable aspect of fluid management. However, 
despite the many changes to the dialysate sodium prescription over the years, there have 
been few randomized controlled clinical trials in this area, hindering consensus regarding the 
optimal approach to dialysate sodium prescription.
Dialysate Sodium in Practice
Preparation of the dialysate
In the modern era, dialysate is generated by mixing commercially-available, pre-formulated 
‘acid’ and ‘bicarbonate’ concentrates. In the U.S. several different formulations with varying 
dialysate sodium concentrations are available. One approach to dialysate solution production 
requires on-site dialysate production with preparation and mixing of the individual acid and 
bicarbonate concentrates according to specific manufacturing guidelines. Another approach 
involves use of premixed acid and base concentrates (i.e. no need for onsite preparation). 
The HD machine proportioning system, the system responsible for the final dialysate 
composition delivered to the patient, combines these concentrated, premixed solutions with 
the water supply to generate the dialysate solution. Within the constraint of delivering an 
electro-neutral solution to the dialysis filter, treating physicians can further manipulate the 
dialysate composition by adjusting the relative dilutions of acid and bicarbonate 
concentrates.
Measurement of dialysate and serum sodium
First, it is important to understand the difference between sodium concentration and sodium 
activity, both of which can be measured in the dialysate and the blood. Sodium concentration 
refers to the number of sodium molecules present per unit of volume. Sodium activity refers 
to ionic activity (the number of sodium ions free in solution and thus available for diffusion 
or chemical reaction). Sodium concentration is greater than sodium activity in solutions 
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where there are other constituents available for binding. Historically, flame photometry, a 
method that captures free and complexed sodium forms, was used to measure physiologic 
fluid sodium levels, and results were adjusted based on protein concentrations. Measurement 
source (blood vs. aqueous fluid) determined the need for result recalibration. Modern 
approaches to serum and dialysate sodium measurement utilize indirect and direct ion-
sensitive electrodes (ISE), which measure sodium activity. Indirect ISE involves a dilution 
step based on the assumed aqueous proportion of the fluid being tested. In the case of 
dialysate, a protein-free liquid, the sodium activity generally approaches the sodium 
concentration. Direct ISE does not require a dilution step, and its results are typically 
‘referenced’ to flame photometric standards for ease of interpretation.17, 18 Studies 
comparing the techniques of flame photometry, direct ISE and indirect ISE among HD 
patients are lacking. Some experts recommend direct ISE as the preferred method for 
dialysate sodium concentration measurement because it does not rely on dilution.19 
However, in today’s practice, indirect ISE is most common in central laboratories.
The intradialytic environment is a dynamic one. During a dialysis treatment, blood 
composition and concentration constantly change, raising the potential for inaccuracies in 
dialysate sodium measurements made by indirect ISE. Furthermore, it is not practical to 
measure dialysate sodium by indirect ISE methods in real-time at each individual HD 
machine. Rather, as sodium is the predominant cation in dialysate, the dialysate conductivity 
can be measured as a surrogate for dialysate sodium concentration. The association between 
dialysate conductivity and dialysate sodium is relatively linear,20 such that a conductivity of 
1 mS/cm is equivalent to a sodium concentration of 10 mEq/L in an aqueous (protein-free) 
solution.21 Therefore, when the dialysate sodium prescription is changed, it is actually the 
dialysate conductivity, not the dialysate sodium concentration per se, that is monitored and 
regulated.
Measured versus prescribed dialysate sodium
The assumption that the prescribed dialysate sodium is equivalent to the delivered 
(measured) dialysate sodium has been challenged in recent times. In a quality improvement 
project, Gul et al. analyzed the difference between measured and prescribed dialysate 
sodium across 333 HD treatments from four dialysis facilities.22 Two of the facilities 
performed weekly on-site dialysate mixing of the acid and base concentrates, and the other 
two facilities used pre-mixed acid concentrates and bicarbonate cartridges. Indirect ISE was 
used to measure the dialysate sodium. The authors found that, on average, 57% of measured 
dialysate sodium concentrations were within ± 2mmol/L of the prescribed dialysate sodium 
concentrations. However, this proportion varied widely, ranging from 25% to 77% across 
facilities. Dialysis facilities utilizing on-site acid and base concentrate mixing exhibited 
greater variability in the measured versus prescribed dialysate sodium. In general, a positive 
bias was observed: measured dialysate sodium tended to be higher than prescribed dialysate 
sodium.22 These findings, however, must be interpreted with caution as the facilities with 
greater variations in prescribed and delivered dialysate sodium were also the facilities 
utilizing individualized dialysate sodium concentrations. Disagreements between prescribed 
and delivered concentrations could thus be attributed to any one or some combination of 1) 
on-site mixing practices, 2) HD machine error or 3) human error.
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This observation highlights important patient care and safety issues related to dialysate 
sodium prescription. Additionally, it underscores the importance of verifying the alignment 
of prescribed and measured dialysate sodium concentrations in future interventional studies 
of dialysate sodium.
There are several processing steps from which discrepancies between prescribed and 
delivered dialysate sodium concentrations can originate. First, individual manufacturers 
accept a specified margin of error (up to 2.5%) in acid and base concentrates.21 These small 
concentration differences can be magnified by the mixing procedures at dialysis facilities. 
One might assume that close monitoring of the dialysate conductivity by the HD machine 
and dialysis facility personnel might negate the influence of margin of error-level differences 
in concentrates. However, small margins of error are also accepted in conductivity 
monitoring. For example, conductivity alarms for some machines do not activate until 
conductivity reaches levels ± 0.5 mS/cm above theoretical conductivity (equivalent to 
dialysate sodium concentrations of ± 5 mEq/L).23 Furthermore, conductivity alarms require 
daily verification with calibration against standard solutions. Within these safeguards, there 
are also margins of error of up to ± 0.3 mS/cm, introducing another potential 2–3 mEq/L 
difference in the dialysate sodium concentration.22 These issues speak to the importance of 
strict attention to facility quality control protocols.
For the remainder of this review, we will assume that the delivered dialysate sodium is equal 
to the prescribed dialysate sodium. However, we caution the reader that this assumption 
cannot be made in clinical practice and therefore, all reported studies of dialysate sodium 
concentrations and outcomes must be viewed as potentially biased by unmeasured, and thus 
unaccounted for, differences in the prescribed and delivered dialysate sodium 
concentrations.
Rationale for Changing the Dialysate Sodium
Sodium removal during dialysis
During the dialysis procedure, sodium is lost via ultrafiltration (a convective process) and 
diffusion. Increased sodium removal can therefore be achieved by either increasing the 
ultrafiltration volume and/or by lowering the dialysate sodium concentration. For diffusive 
removal of sodium to occur, the dialysate sodium concentration must be less than the plasma 
concentration of sodium available for diffusion. There are several competing factors that 
determine the availablity of sodium for diffusion across the dialysis membrane. These 
include: 1) the sodium concentration in plasma water (which is greater than the total plasma 
concentration); 2) the reduction in sodium activity in plasma due to complexing of free 
sodium ions with other anions; and 3) the reduction in sodium activity in plasma due to the 
Gibbs-Donnan effect, which results from negatively charged plasma proteins that cannot 
diffuse across the membrane but complex with sodium. Therefore, in order for diffusive 
sodium removal to occur, it has been estimated that the dialysate sodium must be at least 2 
mEq/L lower than the plasma sodium concentration.24, 25 Due to differences in membrane 
composition, plasma protein content and ultrafiltration volume, the Gibbs Donnan effect is 
variable and may be larger than predicted, further influencing sodium diffusion.16 Thus, 
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even aligning the dialysate sodium concentration to the plasma sodium may result in a net 
positive sodium balance.
Dialytic sodium removal can be measured in the spent dialysate, but this is performed in 
research settings only. In clinical practice, measurement of the sodium removed during 
dialysis is indirect and partially reflected in changes in the serum sodium concentration 
immediately following dialysis. With time, as hypotonic fluid ingestion drives the serum 
sodium back toward a set-point, the serum sodium becomes less reflective of dialytic sodium 
removal. Similar to dialysate sodium measurements, serum sodium measurements are 
subject to variability, and acceptable margins of error have been established for the different 
sodium measurement techniques. Such variability should be considered when prescribing 
the dialysate sodium concentration.
Pathophysiology of dialysate sodium and clinical outcomes
Figure 2 provides an overview of potential pathophysiologic pathways underlying 
associations between dialysate sodium concentrations and clinical outcomes. As dialysis 
technologies have evolved through the years, dialysate sodium concentrations have been 
adjusted to promote tolerability of the HD procedure. In the early years, dialysate sodium 
concentrations were manipulated to minimize rapid reductions in plasma osmolality and 
counteract symptoms associated with the dialysis disequilibrium syndrome. In more recent 
years, changes have targeted hemodynamic stability promotion with an eye toward 
minimizing weight gains and hypertension.
When plasma osmolality rapidly drops during HD (as may occur in with the rapid removal 
of urea and other osmotically active molecules), plasma water moves into the relatively 
hyperosmolar intracellular compartment, leading to intravascular hypovolemia. This 
temporary decline in plasma osmolality also suppresses vasopressin release and promotes 
prostaglandin E2 release, impairing vasoconstriction and reducing vascular tone.26 When 
individuals are exposed to dialysate with sodium concentrations more than 2–3 mEq/L 
below plasma sodium concentrations, this drop in osmolality is amplified by the additional 
effect of sodium loss via diffusion (coupled with convective loss via ultrafiltration). When 
ultrafiltration outpaces plasma refill, and neural and cardiovascular compensatory responses 
are inadequate, BP falls. Intradialytic hypotension has been linked to transient myocardial 
ischemia as evidenced by elevated troponin T levels and episodes of myocardial “stunning” 
on transthoracic echocardiography studies.27–29 Animal studies suggest that repeat ischemic 
insults may lead to left ventricular hypertrophy and the downstream consequences of heart 
failure and arrhythmias.30, 31 Dialysis against a higher dialysate sodium concentration 
promotes hemodynamic stability by improving UF tolerance, both by increasing 
intravascular osmotic pressure and by improving vasoconstrictive compensatory responses.32
While higher dialysate sodium concentrations may have hemodynamic benefits, such 
benefits often come at the expense of volume expansion. When the dialysate sodium 
concentration exceeds the plasma sodium concentration and a patient is “sodium-loaded” 
during treatment, the thirst center is activated, leading to increased weight gains and 
subsequent volume expansion. Total body sodium balance also influences sympathetic tone 
and vasopressin release.8, 10 Data demonstrate that lower dialysate sodium concentrations 
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can lower BP in absence of weight and serum sodium changes,33 suggesting that at least 
some of the net sodium loss occurs from non-dynamic sodium pools (e.g. the intracellular 
space).34 Dialysis against a lower dialysate sodium concentration thus may reduce 
hypertension and its cardiovascular sequelae through both volume-mediated and non-
volume-mediated pathways, though it may prompt intradialytic hemodynamic instability in 
some cases.
Existing Evidence to Guide Selection of Dialysate Sodium Prescription
Evidence supporting use of higher dialysate sodium
Table 1 displays a summary of selected studies that provide support for potential benefits of 
higher dialysate sodium concentrations. Many of the early reports supporting the use of 
higher dialysate sodium focused on symptom outcomes such as muscle cramp 
frequency35, 36 and disequilibrium symptoms.37 A study from the mid-1980’s demonstrated 
an association between fixed higher dialysate sodium concentrations (144 vs. 133 mEq/L) 
and less cramping and fewer episodes of intradialytic hypotension.38 Studies of sodium 
modeling (vs. fixed sodium concentrations) also reported fewer cramps and less pre- to post-
dialysis systolic BP decline.39–41 Overall, changes in dialysis technology and characteristics 
of the end-stage kidney disease population render these early studies poorly generalizable to 
modern practice.
With time, physician-investigators found that a ‘one size fits all’ approach was not realistic 
due to variations in ultrafiltration tolerance and BP control across patients. Such recognition 
prompted the exploration of higher dialysate sodium use among patients prone to 
intradialytic hypotension (vs. all-comers as was studied in the earlier investigations). Several 
studies demonstrated associations between sodium modeling algorithms and fewer 
hypotensive episodes, but such hemodynamic benefits often occurred at the expense of 
greater thirst, weight gains and increased pre-HD BP.42–44 These studies had numerous 
weaknesses including small sample size, inclusion of multiple comparators and short 
durations. Additionally, they do not shed light on the independent contributions of 
interdialytic weight gains (IDWG) and extracellular volume status to outcomes.
Interdialytic weight gain is not an optimal surrogate for extracellular volume status. 
Individuals with lower IDWG may be volume-expanded post-dialysis if target weights are 
over-estimated. Likewise, individuals with larger IDWG may be volume-depleted post-
dialysis if target weights are under-estimated. In both cases, extracellular volume status and 
IDWG are discordant and may independently influence outcomes.45
More recently, several large observational studies have considered dialysate sodium 
concentrations and mortality. Mc Causland et al. examined 2,272 patients from Satellite 
Healthcare and found that higher dialysate sodium concentrations (>140 mEq/L fixed or 
modeled vs. ≤140 mEq/L) were associated with greater mortality - but only among patients 
with higher pre-dialysis serum sodium levels. This finding was in spite of the fact that 
patients with lower serum sodium experienced modestly larger IDWGs.14
Flythe and Mc Causland Page 8
Semin Dial. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Using data from the more sizable Dialysis Outcomes and Practice Patterns Study (DOPPS) 
dataset, Hecking et al. reported that, among all patients, higher dialysate sodium 
concentrations were not associated with greater mortality but were associated with a lower 
risk of hospitalization (HR=0.97 per 2 mEq/L higher dialysate sodium, 95% CI 0.95–1.00, 
P=0.04). In an attempt to minimize confounding by prescribing patterns in relation to the 
mortality risk, they performed sensitivity analyses restricting the sample to facilities where 
more than 90% of patients had the same dialysate sodium; the adjusted HR for mortality 
remained lower (0.88 per 2 mEq/L decrease in dialysate sodium,95%CI 0.83–0.94).46 In a 
second analysis, and among patients with a lower pre-dialysis serum sodium, they reported a 
lower risk of mortality with the use of higher DNa.13 Together, these reports raise the 
possibility that there are select patients in whom the benefit of hemodynamic stabilization 
from higher dialysate sodium outweigh the potential downsides of modest increases in 
IDWG or BP.
Evidence supporting use of lower dialysate sodium
Table 2 displays a summary of selected studies that provide support for potential benefits of 
lower dialysate sodium concentrations. As outlined above, it soon became apparent that the 
hemodynamic benefits of higher dialysate sodium did not come without untoward 
consequences in some patients. Central to these side effects were the observations from early 
studies that patients tended to become thirstier and, consequently, had larger IDWG (and, in 
some cases, higher pre-dialysis BP).47, 48 In a more recent cohort of 30 Turkish HD patients, 
lower dialysate sodium concentration (137 vs. 143 mEq/L) was associated with greater 
brachial artery flow-mediated dilatation, smaller IDWG and lower mean 24 hour ambulatory 
BP (128/77 mmHg vs. 132/81 mmHg). However, these favorable findings came at the 
expense of greater intra-dialytic symptoms such as cramping and hypotension.49
Weight gain, volume expansion and BP change do not always go hand in hand.45 Thein et al. 
noted that a facility-wide decrease in dialysate sodium from 141 to 138 mEq/L was 
associated with a decrease in BP but found no change in IDWG.50 In fact, some studies have 
reported less frequent episodes of intradialytic hypotension with lower dialysate sodium. For 
example, in their crossover study of 27 patients, dePaula et al. noted that individualized 
dialysate sodium (restricted to patients whose pre-HD serum sodium was lower than 137 
mmol/L) vs. fixed dialysate sodium of 138 mEq/L was associated with fewer intra-dialytic 
symptoms. It is important to point out that these patients were all non-diabetic and non-
hypotension prone.51 In an audit of 2,187 British patients, Davenport et al. described less 
intradialytic hypotension with a dialysate sodium concentration 136–137 vs. ≥140 mEq/L.52 
As this was a cross-sectional, clinical audit, it is likely that higher dialysate sodium 
concentrations were preferentially prescribed to hemodynamically unstable patients. Results 
must therefore be interpreted with caution as confounding by indication may introduce bias. 
To our knowledge, there have been no published studies showing an association between 
lower dialysate sodium concentrations and reduced mortality.
Individualization of the dialysate sodium or use of a “sodium alignment” protocol based on 
prior serum sodium measurements is attractive as it would reduce the diffusive sodium flux 
to the patient often associated with standardized dialysate sodium concentrations (typically 
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140 mEq/L) and protect against risk from exposure to overly low dialysate sodium 
concentrations. Relative stability of serum sodium levels over time, driven in part by 
tendency to return to an osmolar set point,16 provides some reassurance regarding the 
reliability of this approach. However, the only supportive data to-date come from small 
studies.51 Furthermore, current dialysis machines require that the dialysate sodium be re-set 
after each treatment. If the machine re-setting step is overlooked, subsequent patients would 
be dialyzed against dialysate sodium concentrations individualized to prior patients, 
potentially introducing risk.
Summary of Evidence
We have presented a summary of published reports that highlight potential benefits and 
drawbacks of the use of higher and lower dialysate sodium prescriptions. Over the last 50 
years, the demographic make-up of the HD population and the technology driving the 
machines used to dialyze them have evolved considerably. Despite these advances and 
notwithstanding a greater appreciation of volume control as a component of dialysis 
adequacy, consensus regarding the optimal approach to dialysate sodium prescription for HD 
patients remains elusive.53–55 Indeed, a recent systematic review of 23 studies also arrived at 
this same conclusion.56 As in the past, and supported by the heterogeneity of the 
associations discussed above, a one-size-fits-all approach is likely not appropriate for the 
modern dialysate sodium prescription. It is likely (and perhaps probable) that the benefits of 
higher dialysate sodium outweigh the downsides for selected individuals, with the converse 
being true for lower dialysate sodium.
Evidence Gaps and Future Directions
In 2014, a coalition of dialysis organization leaders put forward a “Volume First” proposal 
that included a consensus opinion that intradialytic sodium loading should be avoided. They 
recommended prescribing dialysate sodium in the range of 134–138 mEq/L and using 
individualized dialysate sodium prescriptions for patients with relatively stable pre-dialysis 
serum sodium levels. They also called for dialysis machine manufacturers to develop 
machines that default to a standard dialysate sodium concentration between treatments. 
Finally, they advised against the use of hypertonic saline and sodium modeling.53 While 
there are data that support these recommendations, the evidence base is generally weak and 
contains no randomized controlled clinical trials. Furthermore, there are data of similar 
strength that suggest a survival advantage among patients dialyzed with higher dialysate 
sodium. Not surprisingly, others have urged caution in adopting these recommendations.55
To settle the debate regarding the optimal approach to the dialysate sodium prescription, 
randomized controlled clinical trials are needed. Thankfully there is room for optimism in 
this regard as we await the results of several ongoing studies (NCT02823821, 
NCT02145260 and ACTRN12611000975998). Future directions must include building on 
these on-going studies with larger, pragmatically-designed trials that evaluate the safety of 
administering individualized prescriptions to large populations in real-world treatment 
environments.
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Additionally, consideration of whether the serum sodium is even the best reference on which 
to base individualization of dialysate sodium concentrations is warranted. In this regard, a 
recent study highlighted the association of calculated osmolality with greater intradialytic 
systolic BP decline. Mc Causland et al. reported independent associations between higher 
pre-dialysis serum urea nitrogen, higher serum glucose and lower serum sodium levels and 
greater intra-dialytic systolic BP declines.57 These findings suggest that hyponatremia may 
simply be a risk marker, rather than an independent risk factor, for hemodynamic instability 
among HD patients. It also suggests that there may be benefit to clinical interventions aimed 
at minimizing rapid plasma osmolality changes that do not require dialysate sodium 
manipulation and thus avoid the potential downsides of ‘sodium loading’ from higher 
dialysate sodium concentrations.
Conclusion
Volume management plays a key role in the morbidity and mortality experienced by 
individuals receiving HD therapy. Dialysate sodium concentration manipulation represents 
an appealing and underutilized aspect of the HD prescription with regard to the management 
of volume-related clinical issues. Considering the potential benefit of higher dialysate 
sodium concentrations among patients prone to experiencing hemodynamic instability or 
intradialytic symptoms and the potential benefit of lower dialysate sodium among patients 
prone to volume overload and hypertension, the optimal dialysate sodium concentration 
likely varies by person. Identifying the optimal approach to safe delivery of individualized 
dialysate sodium concentrations on a population level is an unmet dialysis delivery system 
need. Ongoing and future research efforts are urgently needed to address this most 
fundamental question in the safe and effective delivery of renal replacement therapy for our 
patients.
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Figure 1. 
History of dialysate sodium titration.
aMost common facility dialysate sodium concentration.12
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Figure 2. 
Proposed pathophysiology underlying dialysate sodium and outcome associations.
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